Table 2. Comparative analytical characteristics and validation evidence of GQD–Au-containing platforms for the detection of cancer biomarkers and cellsa.
| Target | Architecture and readout | Calibration and detection evidence | Selectivity and sample-matrix evidence | Additional analytical evidence | Ref. |
|---|---|---|---|---|---|
| PCA3-associated target DNA | Au–GQD-modified ITO; DNA hybridization monitored by CV | Reported range: 100 fM–1 µM; LOD: 211 fM | CYFRA-21 and cardiac-troponin-I DNA examined individually and with the target; measurements performed in PBS/ferro–ferricyanide electrolyte | Experiments performed using different electrodes, n = 3; response time reported as 5 min, while optimization text describes saturation after 10 min; shelf life approximately 19 ± 1 days | 76 |
| miRNA-21, miRNA-155, and miRNA-210 | AuNPs/GQDs/GO on a three-electrode array; multiplexed SWV | Range: 0.001–1000 pM for each target; respective LODs: 0.04, 0.33, and 0.28 fM | Single-base and triple-base mismatches, non-complementary sequences, and cross-channel interference examined; human-serum application | Respective inter-electrode RSDs: 8.40%, 4.51%, and 9.43%, using 15 fabricated electrodes; target hybridization: 60 min; fabrication plus determination: 4 h 30 min; respective response retention after 21 days at 4 °C: 84.3%, 85.9%, and 89.5% | 77 |
| Glioma cells | Ang-2-conjugated S-GQDs@Au–carbon nanospheres; pulse-assisted EIS | Range: 100–100 000 cells mL−1; LOD: 40 cells mL−1 | Selective glioma-cell detection demonstrated in a human-serum matrix; this matrix experiment should not be interpreted as evidence of patient-derived circulating-tumor-cell detection | An external +0.6 V pulse promotes cell attachment to the recognition interface; the reported analytical performance therefore incorporates electrically assisted capture | 87 |
| PSA | S-GQDs/gold nanostars on a screen-printed electrode; LSV immunosensing | PBS range: 10 fg mL−1–50 ng mL−1; serum range: 100 fg mL−1–35 ng mL−1; respective LODs: 0.29 and 26 fg mL−1 | Discrimination against eight interferents; measurements in PBS and neat human serum | Human-serum recovery: 97–107%; the serum LOD is approximately 90 times higher than the buffer LOD, demonstrating substantial matrix dependence | 78 |
| CD44 | Exfoliated GQDs decorated with AuNPs; antibody-based electrochemical sensing | LOD: 1.17 fg mL−1 in PBS | Anti-CD44 immobilization through EDC/NHS coupling; analytical detection demonstrated in PBS | Electrochemical exfoliation provides GQDs with an approximate diameter of 3 nm, combined with approximately 15 nm AuNPs; the reported detection limit represents buffer-based performance | 79 |
| HepG2 cells | Folic-acid/glutamic-acid-functionalized GQDs–Pd@Au; electrochemical cytosensing | Cell-dependent electrochemical detection using a recognition-active and catalytically amplified hybrid | Folic-acid-mediated cancer-cell recognition; application to human blood | Glutamic-acid functionalization supports electrochemical activity, while Pd@Au contributes catalytic amplification; the measured response reflects the complete multicomponent architecture | 89 |
| CEA | N,S-GQDs/gold nanostars; wash-free fluorescence-recovery immunoassay | Dynamic range: 0.1 pg mL−1–10 µg mL−1; LOD: 64 fg mL−1 | Common ions, amino acids, and PSA examined; human-serum application | Human-serum recovery: 93–106%; wash-free fluorescence recovery provides a solution-phase assay format; stability and reproducibility were examined in the original study | 84 |
| CEA | AuNPs/N-GQDs/rGO; label-free DPV immunosensing | Range: 1 pg mL−1–500 ng mL−1; LOD: 0.13 pg mL−1 | PSA, AFP, NGAL, CA19-9, CA125, and additional interferents examined; tenfold interference challenge; fetal bovine serum diluted 50-fold | Calibration slope: −1.73 ± 0.054 µA per decade of concentration; inter-electrode RSD: 1.8%, n = 5; CEA incubation: 45 min in optimization study; 93.5% response retained after 5 days at 4 °C; serum recovery: 101–103% | 81 |
| CEA | N,S-GQDs/Au–polyaniline nanowires; EIS immunosensing | Range: 0.5–1000 ng mL−1, calibrated against logarithmic concentration; LOD: 0.01 ng mL−1 | AFP, Tau, haemoglobin, l-cysteine, and l-glutamate examined; combined interference mixture increased response by approximately 11.4%; human serum diluted 10-fold | Inter-electrode RSD: 6.8%, n = 5; antigen incubation: 60 min at room temperature; response retained at 4 °C: 98% ± 3%, 92% ± 4%, and 87% ± 4% after 10, 15, and 20 days, respectively; serum recovery: approximately 96.0–103.1% | 80 |
| p53 | Poly-l-cysteine/GQDs/AuNP multilayer interface; SWV and DPV immunosensing | SWV range: 0.000197–0.016 pM; DPV range: 0.195–50 pM; plasma range: 0.000592–1.296 pM; lower quantification limit: 0.065 fM | Measurements in unprocessed human plasma and normal/malignant cell lysates | Different calibration intervals were established for SWV, DPV, and plasma measurements; 0.065 fM is retained as a quantification threshold rather than being reclassified as an LOD | 82 |
| CA 15-3-associated immunoreactivity | Gold nanospears assembled onto thiolated GQDs; SWV immunoassay | Range: 0.16–125 U mL−1; reported detectable concentration: 0.11 U mL−1 | Application to unprocessed human plasma and MCF-7 cell lysates | SWV monitors antigen–antibody binding at the hybrid interface; the conservative target designation accommodates inconsistent antigen/antibody terminology | 83 |
| CEA | GQDs@AuNP-labelled secondary antibody with a P5FIn/erGO capture interface; ECL | Range: 0.1 pg mL−1–10 ng mL−1; LOD: 3.78 fg mL−1 | Human-serum recovery testing; selectivity evaluated | Reproducibility and stability evaluated; analytical amplification combines the P5FIn/erGO capture interface with GQDs@AuNP-labelled secondary antibodies | 86 |
| CEA | Hydrazide-modified GQD–AuNP hybrids on glassy carbon; ECL immunosensing | CEA-dependent ECL attenuation following immunoreaction | Antibody–antigen recognition at the modified electrode | Hybrid formation combines the ECL properties of hydrazide-modified GQDs with the biomolecular assembly capability of AuNPs; the response is interpreted through recognition-induced changes at the electrode interface | 85 |
| Glioma cells | Ang-2/GQDs–nanoporous gold; label-free EIS | Range: 1–106 cells mL−1; LOD: 1 cell mL−1 | Anti-interference against multiple cell lines; spiked human-serum testing | Response retention: 96% after 21 days of storage; measured cell concentrations in serum agreed with the added concentrations | 88 |
| CA-125 | MXene/GQD/AuNP-modified GCE; electrochemical immunosensing | Reported range: 0.1–1 nU mL−1; LOD: 0.075 nU mL−1; units retained as reported | Real-sample testing and selectivity assessment | CV, EIS, SWV, and DPV characterization; reproducibility evaluated | 102 |
| HER2 | Gold-functionalized S,N-GQDs, cobalt porphyrin framework, and their conjugate; EIS immunosensing | Three investigated interfaces gave LODs of 0.0327, 0.0454, and 0.1072 ng mL−1 | Antibody-mediated recognition; human-serum application | Formulation comparison; stability and reproducibility evaluated | 103 |
| HER2 | Gold-functionalized GQD/porphyrin interfaces bearing aptamer or antibody; EIS | Comparative detection performance of alternative recognition elements | Spiked human serum | Aptasensors showed improved detection limits, reusability, and storability relative to the corresponding immunosensors | 104 |
| PSA | PANI/GQD/WOx/Au on graphenized screen-printed carbon electrode; PEC immunosensing | Range: 0.1 pg mL−1–100 ng mL−1; LOD: 75 fg mL−1 | Human serum without dilution or deproteinization | Co-electrodeposition followed by AuNP modification; illumination-dependent photocurrent transduction | 105 |
| Glycan-overexpressing cancer cells | N-GQD-wrapped AuNPs with Raman reporter and boronic-acid targeting ligand; SERS | Targeted cell-surface recognition demonstrated by SERS imaging | Recognition of glycan-overexpressing cancer cells | Electromagnetic and chemical enhancement examined using experimental observations and computational modelling | 106 |
| MCF-7 cells | PHAL-functionalized N,S-GQD/gold-nanostar interface; electrochemical cytosensing | Range: 10–105 cells mL−1; LOD: 3 cells mL−1 | Specificity assessed against other cancer-cell types | Storage assessments extending to 100 days and reuse assessments extending to 30 cycles | 107 |
| BRCA1 | AuNP@ZIF-8 capture interface with N-GQD-labelled secondary antibody; DPV | Range: 1 pg mL−1–50 ng mL−1; LOD: 0.3 pg mL−1 | Interference responses below 5%; spiked-serum recovery: 96.8–104.2% | RSD: 3.8%; 92.5% signal retained after 30 days | 108 |
| Glioma cells | GQD–nanoporous gold nanocomposite | Angiopep-2-mediated recognition; label-free impedimetric detection | Range: 1–106 cells mL−1; reported LOD: 1 cell mL−1; human serum containing added glioma cells; 96% response retained after 21 days of storage; interference evaluated using other cell lines | 88 | |
Entries summarize the reported analytical and validation evidence selected for comparison. Sensitivity denotes the calibration slope and is distinguished from LOD and quantification thresholds. Calibration intervals retain their original concentration-linear, logarithmic, or dynamic-range descriptions. Response times refer to the specified assay step; storage retention describes shelf stability and should not be interpreted as operational stability during repeated use. Differences in matrix dilution, electrolyte, electrode configuration, incubation procedures, and calibration models restrict direct comparisons. Accordingly, the table supports condition-dependent assessment rather than an unconditional ranking of sensor performance.